Launch Intelligence: Connecting Patient Flow, Market Events and Sequencing in One Platform
Forecasts built in isolation break when the market moves. See how connected launch intelligence links patient flow, events and sequencing in one platform.
.jpg)
Beyond the Forecast: Why Launch Decisions Need One Connected View
A launch team hears on a Monday that a competitor has been approved earlier than expected. The forecast that took weeks to build sits in a model few people can open, with its assumptions buried in tabs. The epidemiology came from one source, the market sizing from another, and the access assumptions from a third. Re-running it means rebuilding it. The problem isn’t the team’s skill. It’s that the forecast was never connected to the things that move it.
The Real Cost of Launch Planning Built in Pieces
Most launch planning still treats forecasting as a one-time exercise: a patient funnel in one file, a market view in another, adoption assumptions in a third, and a launch order decided in a meeting. Four failures show up again and again.
The forecast isn’t grounded in the patient journey, because eligible populations and the drop-offs between incidence and treatment are estimated rather than modelled. External events arrive late, because competitor launches, guideline changes, loss of exclusivity and access decisions live outside the model. What-if questions take weeks, because testing a different access, competition or pricing assumption means rebuilding instead of adjusting. And launch order gets decided on instinct, because there is no consistent way to weigh market potential, access, competition and readiness side by side.
The result is a forecast that is out of date by the time it is debated, and a cross-functional room where brand, access and competitive intelligence teams argue over assumptions they can’t see.
Six Modules That Connect Patient Insight to Strategic Decisions
Agilisium’s Launch Intelligence platform is built as six modules that together form an end-to-end view, connecting patient-level insight to strategic decision-making. Each module can also run on its own, depending on what a team needs first.
Epidemiology and patient flow modelling quantifies the patient journey from incidence to treatment, identifying eligible populations and the key drop-offs that drive market opportunity. Market intelligence provides a validated, multi-source view of epidemiology, market size and the current treatment landscape, so every forecast starts from real-world data. Product intelligence models adoption dynamics, including uptake, persistence and switching behaviour, benchmarked against analog products and clinical differentiation.
Event intelligence tracks and builds in external events such as competitor launches, guidelines, loss of exclusivity and access decisions, so they move the forecast when they happen. Scenario simulation enables interactive what-if analysis by adjusting clinical, access, competition and pricing drivers to see the effect on share and revenue. And launch sequencing optimizes market entry using multi-factor scoring across market potential, access, competition and readiness, to maximize global launch value.
One Cycle From Patient Journey to Launch Decision
Used together, the modules follow a connected flow instead of a series of handoffs.
Ground starts with patient flow and market intelligence: who is eligible, where patients drop off, and what the treatment landscape looks like today, validated across sources.
Model brings in product intelligence, turning clinical differentiation and analog benchmarks into uptake, persistence and switching assumptions.
React uses event intelligence to fold in competitor launches, guideline changes, loss of exclusivity and access decisions as they occur, instead of waiting for the next planning cycle.
Decide combines scenario simulation and launch sequencing, so teams can test assumptions and choose where to launch first from the same underlying view.
Four Reasons Connected Launch Intelligence Is Moving Up the Agenda
1. Scenarios run faster. Agilisium’s Launch Intelligence platform targets 65% faster scenario simulation, so what-if questions get answered in the meeting instead of after it.
2. Forecasts become easier to trust. The platform targets 30% higher forecast accuracy by grounding projections in patient flow, validated data and tracked market events, instead of isolated assumptions.
3. Peak share is easier to capture. Timing and sequencing decisions informed by access, competition and readiness support a targeted 25% improvement in peak share capture.
4. Teams work from the same forecast. When every assumption is visible and testable, brand, access and competitive intelligence teams can challenge and validate the logic together instead of debating the output.
A Platform Your Teams Run, Not Another Black Box
Launch tools tend to fall into familiar categories: data suppliers, research-based simulators, forecasting-only models and consulting-led engagements. Each solves a piece. A data supplier provides the inputs, a simulator tests research-based assumptions, a forecasting model produces a number, and a consulting engagement produces a deliverable the team can’t easily re-run.
Agilisium’s approach is different. It integrates the data sources teams already rely on, ties patient flow to revenue, adds market events and sequencing, and gives teams a platform they run themselves. Application and platform engineers build the interactive dashboards and simulation engines, and integrate them with enterprise systems such as BI tools and data platforms, so the intelligence sits where teams already work.
What It Takes to Build It Right
Launch intelligence is as much about people as software. Data engineers build and maintain scalable pipelines that integrate epidemiology, market, access and pipeline intelligence data. Forecasting and analytics experts design the patient flow models, adoption curves and revenue forecasting frameworks. AI and ML engineers develop and calibrate models for adoption prediction, scenario simulation and competitive impact analysis. Oncology and therapeutic-area domain experts keep treatment pathways and market logic clinically accurate.
Brand, access and competitive intelligence stakeholders then provide business context, validate assumptions and turn outputs into decisions. That validation step is what makes the forecast a shared one.
Bringing It All Together: Launch Decisions, Not Just Launch Forecasts
The difference between a forecast and a launch decision is connection. When patient flow, market events, adoption dynamics, scenarios and sequencing draw from the same view, teams stop rebuilding and start deciding. Brand teams see how uptake responds to clinical differentiation. Access teams see how pricing and access assumptions move share. Competitive intelligence teams see market events flow straight into the forecast. Leadership sees which markets to enter first, and why.
One more connection matters: launch order is now a pricing decision. Where a product launches first can shape the price that follows it, which is why launch planning and pricing belong in the same conversation. See how Agilisium’s Pricing Intelligence brings global pricing data together in one place.
Agilisium’s Launch Intelligence platform is built around exactly this shift: six connected modules that give brand, access and competitive intelligence teams one forecast they can see into, test and act on.
Partner with us to see how connected launch intelligence can change how quickly your teams respond when the market moves.
.jpg)
.jpg)
.jpg)
.webp)
.webp)
.webp)
.webp)
.webp)
.webp)
%20(7).avif)
%20(5).avif)
.avif)
